394 related articles for article (PubMed ID: 16207309)
1. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs.
Kukanich B; Lascelles BD; Aman AM; Mealey KL; Papich MG
J Vet Pharmacol Ther; 2005 Oct; 28(5):461-6. PubMed ID: 16207309
[TBL] [Abstract][Full Text] [Related]
2. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.
Zhang Y; Hsieh Y; Izumi T; Lin ET; Benet LZ
J Pharmacol Exp Ther; 1998 Oct; 287(1):246-52. PubMed ID: 9765344
[TBL] [Abstract][Full Text] [Related]
3. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs.
Kuroha M; Shirai Y; Shimoda M
J Vet Pharmacol Ther; 2004 Oct; 27(5):355-9. PubMed ID: 15500574
[TBL] [Abstract][Full Text] [Related]
4. The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs.
Gadeyne C; Van der Heyden S; Gasthuys F; Croubels S; Schauvliege S; Polis I
J Vet Pharmacol Ther; 2011 Oct; 34(5):417-23. PubMed ID: 21241325
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of florfenicol and its metabolite, florfenicol amine, in dogs.
Park BK; Lim JH; Kim MS; Hwang YH; Yun HI
Res Vet Sci; 2008 Feb; 84(1):85-9. PubMed ID: 17570454
[TBL] [Abstract][Full Text] [Related]
6. Analytical determination and pharmacokinetics of robenacoxib in the dog.
Jung M; Lees P; Seewald W; King JN
J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability and pharmacokinetics of oral and injectable formulations of methadone after intravenous, oral, and intragastric administration in horses.
Linardi RL; Stokes AM; Keowen ML; Barker SA; Hosgood GL; Short CR
Am J Vet Res; 2012 Feb; 73(2):290-5. PubMed ID: 22280392
[TBL] [Abstract][Full Text] [Related]
8. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
9. Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs.
Kukanich B; Papich MG
J Vet Pharmacol Ther; 2004 Oct; 27(5):337-41. PubMed ID: 15500572
[TBL] [Abstract][Full Text] [Related]
10. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin.
Hugnet C; Lespine A; Alvinerie M
J Pharm Pharm Sci; 2007; 10(3):311-8. PubMed ID: 17727794
[TBL] [Abstract][Full Text] [Related]
11. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs.
KuKanich B; Papich MG
J Vet Pharmacol Ther; 2004 Aug; 27(4):239-46. PubMed ID: 15305853
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
14. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
15. The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone.
de Castro J; Aguirre C; Rodríguez-Sasiaín JM; Gómez E; Garrido MJ; Calvo R
Biopharm Drug Dispos; 1996 Oct; 17(7):551-63. PubMed ID: 8894114
[TBL] [Abstract][Full Text] [Related]
16. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Chen M; Xu D; Hu XL; Wang H
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
[TBL] [Abstract][Full Text] [Related]
17. A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers.
Jovanović D; Kilibarda V; Maksimović M
Pharmazie; 2001 Oct; 56(10):800-2. PubMed ID: 11683127
[TBL] [Abstract][Full Text] [Related]
18. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.
Abelö A; Eriksson UG; Karlsson MO; Larsson H; Gabrielsson J
J Pharmacol Exp Ther; 2000 Nov; 295(2):662-9. PubMed ID: 11046103
[TBL] [Abstract][Full Text] [Related]
19. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
20. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
